130 related articles for article (PubMed ID: 12510879)
1. Discriminant and quantitative PLS analysis of competitive CYP2C9 inhibitors versus non-inhibitors using alignment independent GRIND descriptors.
Afzelius L; Masimirembwa CM; Karlén A; Andersson TB; Zamora I
J Comput Aided Mol Des; 2002 Jul; 16(7):443-58. PubMed ID: 12510879
[TBL] [Abstract][Full Text] [Related]
2. Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors.
Afzelius L; Zamora I; Masimirembwa CM; Karlén A; Andersson TB; Mecucci S; Baroni M; Cruciani G
J Med Chem; 2004 Feb; 47(4):907-14. PubMed ID: 14761192
[TBL] [Abstract][Full Text] [Related]
3. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors.
Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
Drug Metab Dispos; 2000 Aug; 28(8):994-1002. PubMed ID: 10901712
[TBL] [Abstract][Full Text] [Related]
4. Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis.
Afzelius L; Zamora I; Ridderström M; Andersson TB; Karlén A; Masimirembwa CM
Mol Pharmacol; 2001 Apr; 59(4):909-19. PubMed ID: 11259637
[TBL] [Abstract][Full Text] [Related]
5. Comparative QSAR analyses of competitive CYP2C9 inhibitors using three-dimensional molecular descriptors.
Lather V; Fernandes MX
Chem Biol Drug Des; 2011 Jul; 78(1):112-23. PubMed ID: 21477091
[TBL] [Abstract][Full Text] [Related]
6. Exploring QSAR and QAAR for inhibitors of cytochrome P450 2A6 and 2A5 enzymes using GFA and G/PLS techniques.
Roy K; Roy PP
Eur J Med Chem; 2009 May; 44(5):1941-51. PubMed ID: 19110342
[TBL] [Abstract][Full Text] [Related]
7. GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors.
Pastor M; Cruciani G; McLay I; Pickett S; Clementi S
J Med Chem; 2000 Aug; 43(17):3233-43. PubMed ID: 10966742
[TBL] [Abstract][Full Text] [Related]
8. A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions.
Rao S; Aoyama R; Schrag M; Trager WF; Rettie A; Jones JP
J Med Chem; 2000 Jul; 43(15):2789-96. PubMed ID: 10956186
[TBL] [Abstract][Full Text] [Related]
9. Identification of cytochrome P450 2D6 and 2C9 substrates and inhibitors by QSAR analysis.
Jónsdóttir SÓ; Ringsted T; Nikolov NG; Dybdahl M; Wedebye EB; Niemelä JR
Bioorg Med Chem; 2012 Mar; 20(6):2042-53. PubMed ID: 22364953
[TBL] [Abstract][Full Text] [Related]
10. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
11. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors.
Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
Pharmacogenetics; 1999 Aug; 9(4):477-89. PubMed ID: 10780267
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of recombinant cytochrome P450 isoforms 2D6 and 2C9 by diverse drug-like molecules.
McMasters DR; Torres RA; Crathern SJ; Dooney DL; Nachbar RB; Sheridan RP; Korzekwa KR
J Med Chem; 2007 Jul; 50(14):3205-13. PubMed ID: 17559204
[TBL] [Abstract][Full Text] [Related]
13. Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors.
Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
J Pharmacol Exp Ther; 1999 Jul; 290(1):429-38. PubMed ID: 10381809
[TBL] [Abstract][Full Text] [Related]
14. GRIND/ALMOND investigations on CysLT1 receptor antagonists of the quinolinyl(bridged)aryl type.
Benedetti P; Mannhold R; Cruciani G; Ottaviani G
Bioorg Med Chem; 2004 Jul; 12(13):3607-17. PubMed ID: 15186845
[TBL] [Abstract][Full Text] [Related]
15. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
16. Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.
Roy K; Pratim Roy P
Eur J Med Chem; 2009 Jul; 44(7):2913-22. PubMed ID: 19128860
[TBL] [Abstract][Full Text] [Related]
17. Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.
Zhou SF; Zhou ZW; Yang LP; Cai JP
Curr Med Chem; 2009; 16(27):3480-675. PubMed ID: 19515014
[TBL] [Abstract][Full Text] [Related]
18. CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites.
Ahlström MM; Ridderström M; Zamora I
J Med Chem; 2007 Nov; 50(22):5382-91. PubMed ID: 17915853
[TBL] [Abstract][Full Text] [Related]
19. Conceptual DFT properties-based 3D QSAR: analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme.
Van Damme S; Bultinck P
J Comput Chem; 2009 Sep; 30(12):1749-57. PubMed ID: 19090569
[TBL] [Abstract][Full Text] [Related]
20. Enzyme source effects on CYP2C9 kinetics and inhibition.
Kumar V; Rock DA; Warren CJ; Tracy TS; Wahlstrom JL
Drug Metab Dispos; 2006 Nov; 34(11):1903-8. PubMed ID: 16928789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
